Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a “virtual mode” that is pursuing novel biologically-based and disease-modifying therapeutic solutions for a spectrum of neurodegenerative disorders referred to as tauopathies.  Dysregulation of the Tau protein is the result of some genetic diseases that currently have no effective treatments, and is largely responsible for the onset of Alzheimer’s disease (AD).  By focusing on Tau, we are developing a pipeline of disease-modifying biotherapeutic candidates or products to prevent, delay, or mitigate the underlying dementia or cognitive deficits observed in AD and other related neurodegenerative tauopathies, including:

Frontotemporal dementia (FTD) or Pick’s disease,

Chronic traumatic encephalopathy (CTE) or dementia pugilistica,

Progressive supranuclear palsy (PSP),

Corticobasal degeneration (CBD), and

Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Over the past two decades, the pharmaceutical industry has spent billions of dollars (U.S.) trying to develop potential therapies for AD targeting the beta-amyloid (Aβ) protein as the cause of the disorder.  To date, all have failed in late-stage clinical trials and Tau is now viewed as the much more favorable target, especially since Tau pathology correlates much more closely to the progression of dementia and memory impairment observed in AD than Ab.  We at INT are focused on the underlying mechanisms responsible for Tau dysregulation and dementias, and thereby are developing disease-modifying biotherapeutics to prevent, delay, or ameliorate the cognitive decline resulting from tauopathies.  In addition, we intent to target an “orphan or niche” genetic disorder, such as FTD, PSP, or CBD, with our anti-Tau therapeutic candidates to gain prospective “fast-track” designation through the FDA with smaller and more cost effective clinical trials.  Thus, remaining a virtual company will in turn enable INT to significantly reduce overhead and efficiently advance projects into clinical development.

INT Awarded with Another Phase I SBIR Grant Funding from the National Institute of Health

Innovative NeuroTechnologies, Inc. (INT) in collaboration with Larix Bioscience, LLC have successfully been awarded $224,981 Phase I grant from the National Institute of Health (NIH)/National Institute of Aging (NIA) Small Business Innovation Research (SBIR) program (Federal Award Date: September 21st, 2018) to conduct preliminary “proof-of-concept” animal efficacy studies for a novel “Dual Intracellular and Extracellular Expression (dIEE) Technology for Alzheimer’s Disease (AD).”  The project involves the development of an innovative recombinant adeno-associated viral (AAV) vector to achieve long-term, stable central nervous system (CNS) delivery of an antibody against the key N-terminal domain of the Tau protein (i.e., termed the phosphatase-activating domain or PAD).  This vector will simultaneously deliver an intracellular anti-Tau PAD single-chain intrabody (iAb) combined with a secreted extracellular anti-Tau N-terminal (TNT) antibody (sAb) for the introduction of a novel dual intrabody/antibody approach to mitigate the Tau-mediated pathology and concomitant memory and cognitive impairment observed in AD and other related neurodegenerative tauopathies.

INT Nominated for the Prestigious 2015 Patrick Soon-Shiong Innovation Awards and Symposium Sponsored by the Los Angeles Business Journal

Innovative NeuroTechnologies, Inc. (INT) has been nominated for the prestigious Los Angles Business Journal’s 2015 Patrick Soon-Shiong Innovation Awards and Symposium to take place on Wednesday, November 18th, 2015 at the Four Seasons Hotel in Beverly Hills, CA.  As described by the Los Angeles Business Journal, the program will begin with breakfast and progress through a series of several guest speakers.  Attendees will have an opportunity to be inspired by local innovators sharing their expertise on innovation in California.  The evening portion of the event will be highlighted by the Patrick Soon-Shiong Innovation Awards dinner, where the individuals and organizations that continue to stretch the boundaries and have proven to be leaders in innovation are honored.  INT is certainly thrilled and grateful to be nominated for such an esteemed event and award.

Company News

Recent Posts / View All Posts

Shawn Mojtahedian, Ph.D. to attend the upcoming 48th Annual Neuroscience 2018 Meeting in San Diego, CA

| Company News | No Comments
Shawn Mojtahedian, Ph.D., Founder, President & CEO of Innovative NeuroTechnologies, Inc. to attend the upcoming Society for Neuroscience (SFN) sponsored 48th Annual Neuroscience 2018 Meeting to be held at the…

Shawn Mojtahedian, Ph.D. to attend the upcoming J.P. Morgan 36th Annual Healthcare Conference in San Francisco, CA

| Company News | No Comments
Shawn Mojtahedian, Ph.D., Founder, President & CEO of Innovative NeuroTechnologies, Inc. is scheduled to attend the upcoming J.P. Morgan 36th Annual Healthcare Conference to be held at the Westin St. Francis…

Shawn Mojtahedian, Ph.D. to attend the upcoming 2017 BIO International Convention in San Diego, CA

| Company News | No Comments
Shawn Mojtahedian, Ph.D., Founder, President & CEO of Innovative NeuroTechnologies, Inc. is scheduled to attend the upcoming 2017 BIO International Convention to be held at the San Diego Convention Center…

Shawn Mojtahedian, Ph.D. to attend the upcoming J.P. Morgan 35th Annual Healthcare Conference in San Francisco, CA

| Company News | No Comments
Shawn Mojtahedian, Ph.D., Founder, President & CEO of Innovative NeuroTechnologies, Inc. is scheduled to attend the upcoming J.P. Morgan 35th Annual Healthcare Conference to be held at the Westin St.…

Business Strategy

Innovative NeuroTechnologies, Inc. (INT) is focused on the development of novel and disease-modifying Tau-based biotherapeutics for the treatment of Alzheimer’s disease (AD) and other related human tauopathies, such as frontotemporal dementia (FTD or Pick’s disease) and chronic traumatic encephalopathy (CTE).  INT is currently in the process advancing multiple monoclonal antibody (mAb) candidates against key epitopes of Tau, which are centrally involved in the early conversion of “normal” physiologic Tau to “pathological” Tau, into Phase I clinical trials within the next two to three years as prospective passive immunotherapies for these neurodegenerative conditions.